Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia

Near vision improvements were demonstrated within 30 minutes and lasted up to 10 hours in clinical trials.

  • July 8, 2025

  • 2 min

Share

Objective:

To announce the FDA approval of Vizz (aceclidine ophthalmic solution) for treating presbyopia in adults.

Approach:
    Key Findings:
    • Vizz improves near vision within 30 minutes and lasts up to 10 hours.
    • The treatment contracts the iris sphincter muscle to create a pinhole effect, enhancing depth of focus without inducing a myopic shift.
    • All primary and secondary endpoints for near vision improvement were met in trials.
    Interpretation:

    Vizz offers a new non-surgical option for adults with presbyopia, providing significant near vision improvements without inducing a myopic shift.

    Limitations:
    • Common adverse events included mild and transient symptoms such as instillation site irritation, dim vision, and headache.
    • Long-term effects beyond 6 months were not evaluated in the trials.
    Conclusion:

    Vizz is expected to be available in the U.S. by mid-Q4 2025, providing a promising treatment option for presbyopia.

Original Source(s)

Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia

  • July 8, 2025

Related Content

Which IOLs Are in Your Inventory Closet?

The Ophthalmic ASC spoke with 4 ophthalmologists about the criteria they use for choosing monofocal, toric, multifocal, extended depth of focus (EDOF), and/or presbyopia-correcting intraocular lenses (PCIOLs). They also shared unmet needs in current IOL technology, what their ideal IOL would be if they could design one, and more.

YUVEZZI Campaign Targets Presbyopia

Tenpoint Therapeutic’s new national campaign uses puppet characters to spotlight the everyday frustrations of presbyopia

  • July 13, 2026

  • 2 min
Success and Failure Rates with Increased-Range-of-Focus IOLs 

IRoF lenses offer high success, with some outperforming others